AVEO Pharmaceuticals, Inc. (AVEO) Financial Statements (2024 and earlier)

Company Profile

Business Address 30 WINTER STREET
BOSTON, MA 02108
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 87,32961,76147,74524,42633,52923,348
Cash and cash equivalents 70,54261,76129,78524,42714,94915,096
Short-term investments 16,784 35,920 18,5768,252
Other undisclosed cash, cash equivalents, and short-term investments 3 (17,960)(1)4 
Receivables 9,8111,1971,6313,0264021,027
Inventory, net of allowances, customer advances and progress billings 1,656     
Inventory 1,656     
Other undisclosed current assets 5,9402,5501,22448316,2521,940
Total current assets: 104,73665,50850,60027,93550,18326,315
Noncurrent Assets
Operating lease, right-of-use asset 178903 
Property, plant and equipment 276343    
Other noncurrent assets 151158  1530
Other undisclosed noncurrent assets      940
Total noncurrent assets: 6051,404  15970
TOTAL ASSETS: 105,34166,91250,60027,93550,19827,285
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 13,0967,8433,8026,1974,8943,717
Employee-related liabilities4,963     
Accounts payable 2,7123,3801,4663,4992,4362,186
Accrued liabilities 5,4214,4632,3362,6982,4581,531
Deferred revenue 5781,9741,974
Debt  1,0569,5693,254 2,124
Derivative instruments and hedges, liabilities  199    
Other liabilities  790 300540 
Deferred revenue and credits395510
Contract with customer, liability1,658
Other undisclosed current liabilities 5,0575,0835,7736,70826,2953,998
Total current liabilities: 18,73116,94521,11818,11732,12410,349
Noncurrent Liabilities
Long-term debt and lease obligation 37,96013,0526,19715,77918,47711,879
Long-term debt, excluding current maturities 37,96012,7166,19715,77918,47711,879
Liabilities, other than long-term debt 2,7801,6218,43921,26640,1386,980
Deferred revenue and credits1,3021,697
Deferred revenue  5782,552
Contract with customer, liability3,802
Other liabilities 2,7801,0437907901,090690
Operating lease, liability  336 
Derivative instruments and hedges, liabilities   5,09716,67437,7464,593
Other undisclosed noncurrent liabilities     222 
Total noncurrent liabilities: 40,74014,67314,63637,04558,83718,859
Total liabilities: 59,47131,61835,75455,16290,96129,208
Equity
Equity, attributable to parent 45,87035,29414,846(27,227)(40,763)(1,923)
Common stock 342716112611876
Additional paid in capital 720,386656,472600,306567,655546,092519,911
Accumulated other comprehensive income (loss) (3)  1(4)6
Accumulated deficit (674,547)(621,205)(585,621)(595,009)(586,969)(521,916)
Total equity: 45,87035,29414,846(27,227)(40,763)(1,923)
TOTAL LIABILITIES AND EQUITY: 105,34166,91250,60027,93550,19827,285

Income Statement (P&L) ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 42,2956,01928,7955,4097,5792,515
Cost of revenue
(Cost of Goods and Services Sold)
 (4,737)     
Gross profit: 37,5586,01928,7955,4097,5792,515
Operating expenses (87,112)(44,896)(29,169)(30,766)(36,390)(31,908)
Operating loss: (49,554)(38,877)(374)(25,357)(28,811)(29,393)
Nonoperating income (expense) (3,788)3,2939,76220,028(36,113)2,607
Interest and debt expense  (1,605)(1,815)(2,191)(2,373)(1,949)
Other undisclosed income from continuing operations before equity method investments, income taxes  1,6051,8152,1912,3731,949
Income (loss) from continuing operations before income taxes: (53,342)(35,584)9,388(5,329)(64,924)(26,786)
Income tax expense     (101)(101)
Income (loss) from continuing operations: (53,342)(35,584)9,388(5,329)(65,025)(26,887)
Income (loss) before gain (loss) on sale of properties:(53,342)(35,584)9,388(5,329)(65,025)(26,887)
Net income (loss) available to common stockholders, basic: (53,342)(35,584)9,388(5,329)(65,025)(26,887)
Dilutive securities, effect on basic earnings per share    (19,919)  
Net income (loss) available to common stockholders, diluted: (53,342)(35,584)9,388(25,248)(65,025)(26,887)

Comprehensive Income ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss): (53,342)(35,584)9,388(5,329)(65,025)(26,887)
Comprehensive income (loss): (53,342)(35,584)9,388(5,329)(65,025)(26,887)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (3) (1)5(10)9
Comprehensive income (loss), net of tax, attributable to parent: (53,345)(35,584)9,387(5,324)(65,035)(26,878)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: